These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31336846)

  • 1. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
    Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
    Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
    Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
    Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
    J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 9. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.
    Cioccio J; Claxton D
    Expert Opin Investig Drugs; 2019 Apr; 28(4):337-349. PubMed ID: 30775933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
    Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
    Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.
    Ling Y; Zhang Z; Zhang H; Huang Z
    Curr Pharm Des; 2017 Nov; 23(29):4303-4310. PubMed ID: 28671056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
    Fathi AT; Chen YB
    Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can treating the SYK cell cure leukemia?
    Downing JR
    Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vibsanin A sensitizes human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn.
    Shen X; Xing S; Zhang L; Wang F; Ou H; Shan Y; Xiao H; Xiong G; Wang X; Zhao Q; Cong Y; Yu Z
    Biochem Biophys Res Commun; 2018 Jul; 502(1):110-115. PubMed ID: 29787755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK9 inhibitors in acute myeloid leukemia.
    Boffo S; Damato A; Alfano L; Giordano A
    J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.